Related Experiment Video
Updated: Mar 13, 2026

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
Published on: June 28, 2019
BCRP Inhibition: from Data Collection to Ligand-Based Modeling
Floriane Montanari1, Gerhard F Ecker2
1University of Vienna, Department of Pharmaceutical Chemistry, Althanstrasse 14, 1090 Vienna, Austria phone/fax: +43-1-4277-55110/+43-1-4277-9551.
Abstract:
Breast Cancer Resistance Protein (BCRP, gene ABCG2) is an efflux transporter from the ABC transporters family. It is known to be responsible for the multidrug resistance phenomenon observed in some cancers and is also involved in drug-drug interactions in the liver. Prediction and assessment of inhibition of BCRP is of great interest in the drug development process. This paper presents the largest open dataset currently available for BCRP inhibition, along with the methodology used to compile it. It contains 978 unique compounds with corresponding bioactivities, extracted from 47 studies. The presence of duplicates allowed us to set up thresholds on reported activities to obtain a labelled dataset suitable for learning classification models. Exploratory data analysis and predictive modelling lead to the identification of substructures important for inhibition. We find that the substructures that characterize inhibitors are in line with known SAR relationships of BCRP inhibitors, while the substructures characterizing the non-inhibitors are novel.
Insights
This study introduces the largest open dataset for Breast Cancer Resistance Protein (BCRP) inhibition, aiding drug development. Analysis identified key chemical substructures that predict BCRP inhibition, offering novel insights.
Area of Science:
- Pharmacology
- Biochemistry
- Drug Discovery
Background:
- Breast Cancer Resistance Protein (BCRP), encoded by ABCG2, is an ABC transporter implicated in multidrug resistance and drug-drug interactions.
- Understanding BCRP inhibition is crucial for optimizing cancer therapies and predicting drug behavior.
- Existing datasets for BCRP inhibition lack comprehensive scope, hindering predictive modeling efforts.
Purpose of the Study:
- To present the largest publicly available dataset for BCRP inhibition, comprising 978 unique compounds from 47 studies.
- To develop and validate predictive classification models for BCRP inhibition using this dataset.
- To identify key chemical substructures associated with BCRP inhibition and non-inhibition.
Main Methods:
- Compilation of a comprehensive dataset of BCRP inhibitors and non-inhibitors from diverse scientific literature.
- Application of data cleaning techniques, including duplicate analysis and activity threshold setting, to create a high-quality labeled dataset.
- Utilizing exploratory data analysis and machine learning models to identify structure-activity relationships (SAR) for BCRP inhibition.
Main Results:
- The curated dataset represents the most extensive open resource for BCRP inhibition data to date.
- Predictive modeling successfully identified specific chemical substructures that are characteristic of BCRP inhibitors.
- Novel substructures associated with non-inhibition of BCRP were discovered, expanding the understanding of BCRP SAR.
Conclusions:
- The established dataset and predictive models provide valuable tools for drug discovery and development concerning BCRP.
- The identified substructures offer new insights into the mechanisms of BCRP inhibition and can guide the design of novel therapeutic agents.
- This work facilitates a deeper understanding of BCRP's role in drug resistance and interactions, paving the way for improved drug safety and efficacy.
More Related Videos
08:40An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions
Published on: March 14, 2016
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Related Concept Videos
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
The Equilibrium Binding Constant and Binding Strength
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...